The safety profile of biologic therapies for juvenile idiopathic arthritis (Q37784384)

23 August 2017

The safety profile of biologic therapies for juvenile idiopathic arthritis (English)

1 reference

juvenile rheumatoid arthritis

23 August 2017

1 reference

Philip J Hashkes

1

1 reference

23 August 2017

Yosef Uziel

series ordinal

2

1 reference

23 August 2017

Ronald M Laxer

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

Nature Reviews Rheumatology

23 August 2017

1 reference

23 August 2017

6

1 reference

23 August 2017

10

1 reference

23 August 2017

561-571

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.142

23 August 2017

0 references

cites work

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Medical treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

The German etanercept registry for treatment of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Anti-tumour necrosis factor therapy associated with cutaneous vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Psoriasis after treatment of juvenile idiopathic arthritis with etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.142

Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report

31 March 2020

1 reference

12 December 2020

Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

1 reference

12 December 2020

Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis

1 reference

12 December 2020

Juvenile rheumatoid arthritis: outcome and treatment for the 1990s

1 reference

12 December 2020

1 reference

12 December 2020

Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra)

1 reference

12 December 2020

Abatacept in difficult-to-treat juvenile idiopathic arthritis.

1 reference

12 December 2020

Challenges in the management of juvenile idiopathic arthritis with etanercept

1 reference

12 December 2020

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

1 reference

12 December 2020

Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis

1 reference

12 December 2020

Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis

1 reference

12 December 2020

Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.

1 reference

12 December 2020

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.

1 reference

12 December 2020

Optic neuritis associated with etanercept therapy for juvenile arthritis

1 reference

12 December 2020

Dismantling the pyramid

1 reference

12 December 2020

Mortality outcomes in pediatric rheumatology in the US.

1 reference

12 December 2020

Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis

1 reference

12 December 2020

[Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.142

1 reference

23 August 2017

1 reference